X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
TNX-601 ER (tianeptine hemioxalate extended-release tablets) is a novel oral formulation of tianeptine designed for once-daily daytime dosing. It is under phase 2 clinical development for the treatment of major depressive disorder (MDD).
Lead Product(s): Tianeptine Oxalate
Therapeutic Area: Psychiatry/Psychology Product Name: TNX-601
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 31, 2023
Details:
TNX-601 ER (tianeptine hemioxalate extended release) is being developed as a potential treatment for major depressive disorder (MDD), posttraumatic stress disorder (PTSD) and neurocognitive dysfunction associated with corticosteroid use.
Lead Product(s): Tianeptine Oxalate
Therapeutic Area: Psychiatry/Psychology Product Name: TNX-601
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 16, 2023
Details:
TNX-601 ER (tianeptine hemioxalate extended release) is being developed as a potential treatment for major depressive disorder (MDD), posttraumatic stress disorder (PTSD) and neurocognitive dysfunction associated with corticosteroid use.
Lead Product(s): Tianeptine Oxalate
Therapeutic Area: Psychiatry/Psychology Product Name: TNX-601
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 24, 2023
Details:
TNX-601 ER (tianeptine hemioxalate) is an agonist for the nuclear peroxisome proliferator-activated receptor isoforms PPAR-β/δ and PPAR-γ, which account for its ability to induce neuroplasticity in cultured neurons, for the treatment of depression.
Lead Product(s): Tianeptine Oxalate
Therapeutic Area: Psychiatry/Psychology Product Name: TNX-601
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2023
Details:
TNX-601 (tianeptine hemioxalate) is an antidepressant agent with a novel neurochemical profile. It increases serotonin (5-hydroxytryptamine) uptake in the brain (in contrast with most antidepressant agents) and reduces stress-induced atrophy of neuronal dendrites.
Lead Product(s): Tianeptine Oxalate
Therapeutic Area: Psychiatry/Psychology Product Name: TNX-601
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 16, 2023
Details:
TNX-601 CR (tianeptine oxalate and naloxone controlled-release) for MDD, that was designed to mitigate the risk of parenteral abuse. TNX-601 ER is also designed with abuse deterrent properties but without the µ-opioid receptor antagonist naloxone.
Lead Product(s): Tianeptine Oxalate,Naloxone Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: TNX-601
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 03, 2022
Details:
TNX-601 ER (tianeptine oxalate) is a novel oral formulation of tianeptine oxalate designed for once-daily daytime dosing that is in the pre-IND (Investigational New Drug) stage of development for the treatment of MDD.
Lead Product(s): Tianeptine Oxalate,Naloxone Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: TNX-601
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 11, 2022
Details:
Based on this study, the final formulation of TNX-601 CR to be used in Phase 2 testing will be 39.4 mg tianeptine oxalate and 1 mg naloxone for once daily treatment of MDD. Naloxone is included in the formulation to mitigate the potential for high dose parenteral abuse.
Lead Product(s): Tianeptine Oxalate,Naloxone Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: TNX-601 CR
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
